Denial of Methadone Devastates Incarcerated People: What Hope?

When people who are dependent on opioids are incarcerated and denied access, they go into withdrawal—an often-painful condition with symptoms that include vomiting and diarrhea. Some incarcerated people have even died from this enforced “cold turkey.”

Yet the huge majority of such people in US prisons and jails do not receive the medications that could spare them this experience—and even more importantly, greatly improve their chances of survival after release.

Denial of Methadone Devastates Incarcerated People: What Hope?

Denial of Methadone Devastates Incarcerated People: What Hope?

BY ALISON KNOPF / JUNE 4, 2019
When people who are dependent on opioids are incarcerated and denied access, they go into withdrawal—an often-painful condition with symptoms that include vomiting and diarrhea. Some incarcerated people have even died from this enforced “cold turkey.”

Yet the huge majority of such people in US prisons and jails do not receive the medications that could spare them this experience—and even more importantly, greatly improve their chances of survival after release.

Full article at:

Denial of Methadone Devastates Incarcerated People: What Hope?

The Health Resources and Services Administration’s (HRSA) Federal Office of Rural Health Policy (FORHP) will be releasing a Notice of Funding Opportunity (NOFO) for a new Rural Communities Opioid Response Program (RCORP) initiative called RCORP-Implementation (HRSA-19-082).

Successful RCORP-Implementation award recipients will receive up to $1 million for a three-year period of performance to enhance and expand substance use disorder (SUD), including opioid use disorder (OUD), service delivery in high-risk rural communities. Award recipients will implement a set of core SUD/OUD prevention, treatment, and recovery activities that align with the U.S. Department of Health and Human Services’ (HHS) Five-Point Strategy to Combat the Opioid Crisis (PDF – 76 KB).

Award recipients are encouraged to leverage workforce recruitment and retention programs like the National Health Service Corps (NHSC). We encourage you to learn more about how to become an NHSC site and NHSC site benefits. NHSC-approved sites provide outpatient, primary healthcare services to people in health professional shortage areas.

All domestic public and private entities, nonprofit and for-profit, will be eligible to apply and all services must be provided in HRSA-designated rural areas (as defined by the Rural Health Grants Eligibility Analyzer). Applicants do not need to be current or former RCORP-Planning award recipients to apply for this funding opportunity.

The applicant organization must be part of an established network or consortium that includes at least three other separately-owned (i.e., different Employment Identification Numbers) entities. At least two of these entities must be located in a HRSA-designated rural area.

RCORP is a multi-year initiative by HRSA aimed at supporting treatment for and prevention of SUD/OUD. In FY18, HRSA awarded 95 grants to rural communities under the RCORP-Planning initiative and funded a technical assistance center to support RCORP award recipients. In FY19, in addition to the RCORP-Implementation awards, HRSA anticipates awarding a new round of RCORP-Planning grants and launching a pilot grant program aimed at expanding the number of small rural hospitals and clinics that provide medication-assisted treatment.

You can subscribe to receive updates on this and other funding opportunities through grants.gov: https://www.grants.gov/manage-subscriptions.html. Potential applicants are encouraged to register early with grants.gov, SAM, and DUNS, as the registration process can take up to a month to complete.

For more information about RCORP, please contact Federal Office of Rural Health Policy. To learn more about how HRSA is addressing the opioid epidemic, visit https://www.hrsa.gov/opioids.

FDA approves prescription app for outpatient use disorder patients

The Food and Drug Administration yesterday approved a Mobile Medical application to help increase retention in outpatient treatment programs for opioid use disorder. The app can be downloaded to a patient’s mobile device with a prescription from his/her doctor to use while participating in an outpatient treatment program under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management.

“As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” said FDA Commissioner Scott Gottlieb, M.D. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”